Biosynthesis of thromboxane in patients with systemic sclerosis and Raynaud's phenomenon.

Preliminary criteria for the classification of systemic sclerosis (scleroderma)

1980 • 4,703 citations

Aggregation of Blood Platelets by Adenosine Diphosphate and its Reversal

1962 • 4,273 citations

Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides.

1975 • 3,075 citations

Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man.

1983 • 675 citations

Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects

1980 • 642 citations

Release of Prostaglandins and Thromboxane into the Coronary Circulation in Patients with Ischemic Heart Disease

1981 • 597 citations

Plasma levels of beta-thromboglobulin and platelet factor 4 as indices of platelet activation in vivo

1981 • 511 citations

Increased Prostacyclin Biosynthesis in Patients with Severe Atherosclerosis and Platelet Activation

1984 • 510 citations

Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease.

1983 • 464 citations

Estimated rate of prostacyclin secretion into the circulation of normal man.

1981 • 271 citations

Metabolism of thromboxane B2 in man. Identification of twenty urinary metabolites.

1981 • 244 citations

Morphologic Changes in the Digital Arteries of Patients with Progressive Systemic Sclerosis (Scleroderma) and Raynaud Phenomenon

1980 • 236 citations

Estimated rate of thromboxane secretion into the circulation of normal humans.

1986 • 234 citations

Application of imidazole as a selective inhibitor thromboxane synthetase in human platelets.

1977 • 215 citations

Monitoring the entry of new platelets into the circulation after ingestion of aspirin

1983 • 142 citations

Elevated Levels of Circulating Platelet Aggregates and Beta-Thromboglobulin in Scleroderma

1982 • 123 citations

The biochemical pharmacology of thromboxane synthase inhibition in man.

1985 • 122 citations

Increased thromboxane biosynthesis in a human preparation of platelet activation: biochemical and functional consequences of selective inhibition of thromboxane synthase.

1986 • 114 citations

Measurement of urinary 2,3-dinor-thromboxane B2 and thromboxane B2 using bonded-phase phenylboronic acid columns and capillary gas chromatography-negative-ion chemical ionization mass spectrometry

1985 • 100 citations

Raynaud's Disease, Raynaud's Phenomenon, and Serotonin

1960 • 88 citations

Role of cold and emotional stress in Raynaud's disease and scleroderma.

1983 • 70 citations

Endogenous biosynthesis of prostacyclin during cardiac catheterization and angiography in man.

1985 • 64 citations

Controlled double-blind trial of dazoxiben and nifedipine in the treatment of Raynaud's phenomenon

1984 • 57 citations

Pathogenesis of Scleroderma (Systemic Sclerosis)

1982 • 41 citations

Plasma exchange and platelet function in Raynaud's phenomenon

1980 • 40 citations

Dazoxiben, a thromboxane synthetase inhibitor, in the treatment of Raynaud's syndrome: a double-blind trial.

1983 • 39 citations

Analysis of urinary metabolites of thromboxane and prostacyclin by negative-ion chemical-ionization gas chromatography/mass spectrometry.

1985 • 32 citations

Potentiation by dazoxiben, a thromboxane synthetase inhibitor, of platelet aggregation inhibitory activity of a thromboxane receptor antagonist and of prostacyclin

1982 • 31 citations

Dazoxiben, a thromboxane synthetase inhibitor, in Raynaud's phenomenon

1984 • 25 citations

Effect of thromboxane synthetase inhibition in Raynaud's phenomenon

1984 • 21 citations

Effects of thromboxane antagonist EP 045 on platelet aggregation.

1983 • 15 citations

A thromboxane synthetase inhibitor in Raynaud's phenomenon

1983 • 10 citations